Cara Therapeutics Stock Forecast, Price & News

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

Is Cara Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics or view top-rated stocks.

How has Cara Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CARA stock has decreased by 8.3% and is now trading at $12.31.
View which stocks have been most impacted by COVID-19.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 2,900,000 shares, an increase of 37.4% from the October 14th total of 2,110,000 shares. Based on an average trading volume of 1,640,000 shares, the short-interest ratio is presently 1.8 days. Currently, 7.3% of the shares of the stock are short sold.
View Cara Therapeutics' Short Interest.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cara Therapeutics.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.34. Cara Therapeutics had a trailing twelve-month return on equity of 10.72% and a net margin of 10.88%. During the same period in the prior year, the business posted ($0.35) earnings per share.
View Cara Therapeutics' earnings history.

What price target have analysts set for CARA?

3 equities research analysts have issued 1-year target prices for Cara Therapeutics' shares. Their forecasts range from $16.00 to $35.00. On average, they expect Cara Therapeutics' share price to reach $25.67 in the next year. This suggests a possible upside of 108.5% from the stock's current price.
View analysts' price targets for Cara Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the following people:

• Derek T. Chalmers, President, Chief Executive Officer & Director
• Thomas Reilly, Chief Financial & Accounting Officer
• Frèdèrique Menzaghi, Chief Scientific Officer, Senior VP-R&D
• Joana Goncalves, Chief Medical Officer (LinkedIn Profile)
• Scott M. Terrillion, Secretary & Chief Compliance Officer (LinkedIn Profile)

Who are some of Cara Therapeutics' key competitors?

Some companies that are related to Cara Therapeutics include OPKO Health (OPK), Schrödinger (SDGR), Ligand Pharmaceuticals (LGND), PTC Therapeutics (PTCT), ChemoCentryx (CCXI), Corcept Therapeutics (CORT), Aurinia Pharmaceuticals (AUPH), Pacira BioSciences (PCRX), Emergent BioSolutions (EBS), TG Therapeutics (TGTX), Sage Therapeutics (SAGE), Prothena (PRTA), Lyell Immunopharma (LYEL), Harmony Biosciences (HRMY) and Xencor (XNCR).
View all of CARA's competitors.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), 22nd Century Group (XXII), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.19%), Geode Capital Management LLC (1.67%), Kingdon Capital Management L.L.C. (1.34%), Bank of New York Mellon Corp (0.77%), Dimensional Fund Advisors LP (0.66%) and Principal Financial Group Inc. (0.70%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends for Cara Therapeutics.

Which institutional investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, BlackRock Inc., Morgan Stanley, Deutsche Bank AG, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Penserra Capital Management LLC, and First Quadrant L P CA. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion, and Thomas Charles Reilly.
View insider buying and selling activity for Cara Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Connor Clark & Lunn Investment Management Ltd., Davy Global Fund Management Ltd, Two Sigma Investments LP, Brandywine Global Investment Management LLC, SG Americas Securities LLC, Vident Investment Advisory LLC, and Jane Street Group LLC.
View insider buying and selling activity for Cara Therapeutics or or view top insider-buying stocks.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $12.31.

How much money does Cara Therapeutics make?

Cara Therapeutics has a market capitalization of $658.08 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.49 on an earnings per share basis.

How many employees does Cara Therapeutics have?

Cara Therapeutics employs 80 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is www.caratherapeutics.com.

Where are Cara Therapeutics' headquarters?

Cara Therapeutics is headquartered at 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at [email protected], or via fax at 203-567-1510.